| 55.95 0.405 (0.73%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 68.04 | 1-year : | 79.47 |
| Resists | First : | 58.25 | Second : | 68.04 |
| Pivot price | 55.18  |
|||
| Supports | First : | 52.69 | Second : | 49.25 |
| MAs | MA(5) : | 56.42  |
MA(20) : | 54.16 |
| MA(100) : | 56.37 |
MA(250) : | 56.09 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 64.6 |
D(3) : | 75.9 |
| RSI | RSI(14): 53.9 |
|||
| 52-week | High : | 66.27 | Low : | 49.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BMRN ] has closed below upper band by 38.8%. Bollinger Bands are 17.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 56.34 - 56.66 | 56.66 - 56.94 |
| Low: | 54.64 - 55.05 | 55.05 - 55.44 |
| Close: | 55.35 - 55.95 | 55.95 - 56.5 |
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
Fri, 12 Jun 2026
Janus Henderson High-Yield Fund's BioMarin Pharmaceutical Inc(BMRN) Holding History - GuruFocus
Wed, 10 Jun 2026
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals - ChartMill
Mon, 08 Jun 2026
Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years - Yahoo Finance
Thu, 04 Jun 2026
BioMarin (BMRN) director receives 7,490 RSUs in stock grant - Stock Titan
Thu, 04 Jun 2026
BioMarin (BMRN) director Ian T. Clark awarded 7,490 restricted stock units - Stock Titan
Sat, 30 May 2026
BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 193 (M) |
| Shares Float | 192 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 102.7 (%) |
| Shares Short | 11,360 (K) |
| Shares Short P.Month | 10,150 (K) |
| EPS | 1.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 32.13 |
| Profit Margin | 8.2 % |
| Operating Margin | 18 % |
| Return on Assets (ttm) | 4.4 % |
| Return on Equity (ttm) | 4.4 % |
| Qtrly Rev. Growth | 2.7 % |
| Gross Profit (p.s.) | 8.58 |
| Sales Per Share | 16.76 |
| EBITDA (p.s.) | 3.26 |
| Qtrly Earnings Growth | -43.1 % |
| Operating Cash Flow | 874 (M) |
| Levered Free Cash Flow | 459 (M) |
| PE Ratio | 40.25 |
| PEG Ratio | 0.6 |
| Price to Book value | 1.74 |
| Price to Sales | 3.33 |
| Price to Cash Flow | 12.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|